BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

Más betegség

• Current or planned treatment of another tumor disease except keratoacanthoma, squamous cell or basal cell carcinoma of the skin

Egyéb

• Lack of basic demographics and staging information
• Current or planned participation within a clinical trial. The participation in a follow-up phase of a clinical trial without active intervention is allowed.

• Patients with complete surgical resection of histologically confirmed AJCC (American Joint Committee on Cancer) (8th edition) clinical stage III (IIIA, IIIB, IIIC, IIID) melanoma, for whom a decision for adjuvant treatment with dabrafenib and trametinib has been made before entering the study.
• V600E/K mutation-positive cutaneous melanoma
• Adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) as indicated in the SmPC (Summary of Product Characteristics) and by prescription, that has been started no longer that 4 weeks before inclusion of the patient into the study or which will be initiated directly after inclusion
• Age ≥ 18 years
• Signed written informed consent